目的 了解鲍曼不动杆菌的临床分布及其对常用抗生素的耐药情况，为临床合理用药提供依据。方法 回顾性分析临床标本中分离的鲍曼不动杆菌的分布及其药敏结果。结果 共检出309株鲍曼不动杆菌。在临床标本中，痰液分布率最高，占88.03%;科室分布以ICU为主，占50.16%。药敏结果显示:对黏菌素和多黏菌素较敏感，耐药率低于10%;对头孢哌酮/舒巴坦的耐药率较低(17.5%);对米诺环素和左氧氟沙星的耐药率低于50%，对其余19 种抗生素耐药率均高于50%;其中对头孢哌酮、诺氟沙星和氧氟沙星的耐药率达到100%。结论 鲍曼不动杆菌对黏菌素、多黏菌素和头孢哌酮/舒巴坦较敏感，对碳氢酶烯的耐药率增高，应加强鲍曼不动杆菌的耐药性监测，为临床合理选用抗生素提供依据。同时，应对泛耐药鲍曼不动杆菌采取有效的预防措施，避免泛耐药菌株的暴发流行。

Objective To investigate the clinical distribution and the drug resistance of Acinetobacter baumannii, and to provide guidance for clinical medication. Methods Specimens were collected from clinical patients with infection from January to December in 2012.Strains of Acinetobacter baumannii were isolated and the drug sensitivity was tested retrospectively. Results A total of 309 strains of Acinetobacter baumannii were isolated, sputum was the main specimen from which Acinetobacter baumannii were isolated (88.03%). Acinetobacter baumannii was mainly distributed at ICU (50.16%). These strains were susceptible to colistin and polymyxin, the drug resistance rate of which is lower than 10%. The drug resistance rate to cefoperazone/sulbactam was 17.5%. The drug resistance rate to other 19 antibiotics was higher than 50%. The highest resistance rate was 100%, which was cefoperazone, to norfboxacin and to ofloxacin. Conclusions Acinetobacter baumannii is susceptible to colistin, polymyxin and cefoperazone/sulbactam. In order to provide the basic evidence for selecting the antibiotics reasonably in clinic, we should strengthen monitoring the drug resistance of Acinetobacter baumannii. Meanwhile we should take effective preventive measures to avoid outbreak of Acinetobacter baumannii infection to avoid outbreak. Antimicrobial agents should be used rationally to decrease multi - drug resistance.